JP2019510478A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019510478A5 JP2019510478A5 JP2018541289A JP2018541289A JP2019510478A5 JP 2019510478 A5 JP2019510478 A5 JP 2019510478A5 JP 2018541289 A JP2018541289 A JP 2018541289A JP 2018541289 A JP2018541289 A JP 2018541289A JP 2019510478 A5 JP2019510478 A5 JP 2019510478A5
- Authority
- JP
- Japan
- Prior art keywords
- chimeric protein
- protein according
- antibody
- mutation
- recognition domain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022110687A JP2022153437A (ja) | 2016-02-05 | 2022-07-08 | 標的療法剤およびその使用 |
| JP2024133824A JP2024164840A (ja) | 2016-02-05 | 2024-08-09 | 標的療法剤およびその使用 |
Applications Claiming Priority (25)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662291774P | 2016-02-05 | 2016-02-05 | |
| US201662291779P | 2016-02-05 | 2016-02-05 | |
| US201662291772P | 2016-02-05 | 2016-02-05 | |
| US201662291776P | 2016-02-05 | 2016-02-05 | |
| US201662291769P | 2016-02-05 | 2016-02-05 | |
| US62/291,776 | 2016-02-05 | ||
| US62/291,774 | 2016-02-05 | ||
| US62/291,779 | 2016-02-05 | ||
| US62/291,769 | 2016-02-05 | ||
| US62/291,772 | 2016-02-05 | ||
| US201662336030P | 2016-05-13 | 2016-05-13 | |
| US201662335965P | 2016-05-13 | 2016-05-13 | |
| US201662335880P | 2016-05-13 | 2016-05-13 | |
| US201662335968P | 2016-05-13 | 2016-05-13 | |
| US201662335979P | 2016-05-13 | 2016-05-13 | |
| US62/335,880 | 2016-05-13 | ||
| US62/336,030 | 2016-05-13 | ||
| US62/335,979 | 2016-05-13 | ||
| US62/335,968 | 2016-05-13 | ||
| US62/335,965 | 2016-05-13 | ||
| US201662353607P | 2016-06-23 | 2016-06-23 | |
| US62/353,607 | 2016-06-23 | ||
| US201662411805P | 2016-10-24 | 2016-10-24 | |
| US62/411,805 | 2016-10-24 | ||
| PCT/EP2017/052545 WO2017134302A2 (en) | 2016-02-05 | 2017-02-06 | Targeted therapeutic agents and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022110687A Division JP2022153437A (ja) | 2016-02-05 | 2022-07-08 | 標的療法剤およびその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019510478A JP2019510478A (ja) | 2019-04-18 |
| JP2019510478A5 true JP2019510478A5 (https=) | 2020-03-19 |
| JP7166923B2 JP7166923B2 (ja) | 2022-11-08 |
Family
ID=57995193
Family Applications (7)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018540141A Active JP6991979B2 (ja) | 2016-02-05 | 2017-02-06 | Ｃｄ８結合物質 |
| JP2018541133A Active JP7236273B2 (ja) | 2016-02-05 | 2017-02-06 | Ｃｌｅｃ９ａ結合物質 |
| JP2018541357A Active JP7030704B2 (ja) | 2016-02-05 | 2017-02-06 | 二重特異性シグナル伝達物質およびその使用 |
| JP2018541289A Active JP7166923B2 (ja) | 2016-02-05 | 2017-02-06 | 標的療法剤およびその使用 |
| JP2022025686A Active JP7386277B2 (ja) | 2016-02-05 | 2022-02-22 | 二重特異性シグナル伝達物質およびその使用 |
| JP2022110687A Pending JP2022153437A (ja) | 2016-02-05 | 2022-07-08 | 標的療法剤およびその使用 |
| JP2024133824A Pending JP2024164840A (ja) | 2016-02-05 | 2024-08-09 | 標的療法剤およびその使用 |
Family Applications Before (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018540141A Active JP6991979B2 (ja) | 2016-02-05 | 2017-02-06 | Ｃｄ８結合物質 |
| JP2018541133A Active JP7236273B2 (ja) | 2016-02-05 | 2017-02-06 | Ｃｌｅｃ９ａ結合物質 |
| JP2018541357A Active JP7030704B2 (ja) | 2016-02-05 | 2017-02-06 | 二重特異性シグナル伝達物質およびその使用 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022025686A Active JP7386277B2 (ja) | 2016-02-05 | 2022-02-22 | 二重特異性シグナル伝達物質およびその使用 |
| JP2022110687A Pending JP2022153437A (ja) | 2016-02-05 | 2022-07-08 | 標的療法剤およびその使用 |
| JP2024133824A Pending JP2024164840A (ja) | 2016-02-05 | 2024-08-09 | 標的療法剤およびその使用 |
Country Status (8)
| Country | Link |
|---|---|
| US (7) | US10988538B2 (https=) |
| EP (8) | EP3411407B1 (https=) |
| JP (7) | JP6991979B2 (https=) |
| CN (9) | CN116769054A (https=) |
| CA (4) | CA3013551A1 (https=) |
| DK (3) | DK3411407T3 (https=) |
| ES (3) | ES2877568T3 (https=) |
| WO (4) | WO2017134305A1 (https=) |
Families Citing this family (105)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116769054A (zh) * | 2016-02-05 | 2023-09-19 | 奥里尼斯生物科学私人有限公司 | 双特异性信号传导剂及其用途 |
| EP3455245A2 (en) * | 2016-05-13 | 2019-03-20 | Orionis Biosciences NV | Therapeutic targeting of non-cellular structures |
| CN110573172A (zh) | 2017-02-06 | 2019-12-13 | 奥里尼斯生物科学有限公司 | 靶向的工程化干扰素及其用途 |
| KR102642385B1 (ko) | 2017-02-06 | 2024-03-04 | 오리오니스 바이오사이언시스 엔브이 | 표적화된 키메라 단백질 및 이의 용도 |
| EP3596108A4 (en) | 2017-03-15 | 2020-12-23 | Pandion Operations, Inc. | TARGETED IMMUNOTOLERANCE |
| US10676516B2 (en) | 2017-05-24 | 2020-06-09 | Pandion Therapeutics, Inc. | Targeted immunotolerance |
| JP2020530280A (ja) | 2017-07-03 | 2020-10-22 | トルク セラピューティクス， インコーポレイテッド | 免疫刺激性融合分子およびその使用 |
| EP4029877B1 (en) | 2017-08-03 | 2024-01-17 | Amgen Inc. | Interleukin-21 muteins and methods of treatment |
| AU2018313810B2 (en) * | 2017-08-09 | 2025-05-15 | Orionis Biosciences BV | Clec9A binding agents and use thereof |
| EP3664829A4 (en) | 2017-08-09 | 2021-05-05 | Orionis Biosciences, Inc. | LIAISON OFFICERS AT PD-1 AND PD-L1 |
| CN111511763B (zh) | 2017-08-09 | 2024-05-31 | 奥里尼斯生物科学有限公司 | Cd8结合剂 |
| EP3668893A4 (en) * | 2017-08-16 | 2021-08-04 | Dragonfly Therapeutics, Inc. | PROTEINS BINDING TO NKG2D, CD16 AND EGFR, HLA-E, CCR4, OR PD-L1 |
| US10946068B2 (en) | 2017-12-06 | 2021-03-16 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
| US10174092B1 (en) | 2017-12-06 | 2019-01-08 | Pandion Therapeutics, Inc. | IL-2 muteins |
| USRE50550E1 (en) | 2017-12-06 | 2025-08-26 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
| TW201930344A (zh) | 2018-01-12 | 2019-08-01 | 美商安進公司 | 抗ｐｄ-１抗體及治療方法 |
| WO2019147837A2 (en) | 2018-01-24 | 2019-08-01 | Beijing Percans Oncology Co. Ltd. | Cytokine fusion proteins |
| WO2020113403A1 (en) * | 2018-12-04 | 2020-06-11 | Beijing Percans Oncology Co. Ltd. | Cytokine fusion proteins |
| EP3743448A4 (en) * | 2018-01-26 | 2021-11-03 | Orionis Biosciences, Inc. | XCR1 BINDING AGENTS AND USES THEREOF |
| KR102877915B1 (ko) | 2018-02-05 | 2025-10-29 | 오리오니스 바이오사이언시즈 인코포레이티드 | 섬유아세포 결합제 및 이의 용도 |
| KR20210005872A (ko) * | 2018-03-28 | 2021-01-15 | 오리오니스 바이오사이언시즈 인코포레이티드 | 이작용성 단백질 및 이의 작제물 |
| CN108727504B (zh) * | 2018-04-16 | 2021-08-27 | 泉州向日葵生物科技有限公司 | 一种ifn与抗pd-l1抗体的融合蛋白及其应用 |
| CA3097396A1 (en) * | 2018-04-19 | 2019-10-24 | Baylor College Of Medicine | Reprogramming cd4 t cells into cytotoxic cd8 cells by forced expression of cd8ab and class 1 restricted t cell receptors |
| WO2019227490A1 (en) | 2018-06-01 | 2019-12-05 | Tayu Huaxia Biotech Medical Group Co., Ltd. | Compositions and methods for imaging |
| EP3818085A4 (en) | 2018-06-01 | 2022-03-09 | Tayu Huaxia Biotech Medical Group Co., Ltd. | COMPOSITIONS AND THEIR USES FOR THE TREATMENT OF DISEASES OR DISORDERS |
| CN112399973B (zh) * | 2018-06-05 | 2022-12-16 | 江苏康宁杰瑞生物制药有限公司 | 二聚体及其用途 |
| US20210347849A1 (en) * | 2018-07-24 | 2021-11-11 | Good T Cells, Inc. | Composition for Preventing or Treating Immune-Related Diseases |
| EP3826673A4 (en) * | 2018-07-26 | 2022-03-09 | Tayu Huaxia Biotech Medical Group Co., Ltd. | COMPOSITIONS AND METHODS FOR IMAGING |
| WO2020033646A1 (en) | 2018-08-08 | 2020-02-13 | Orionis Biosciences, Inc. | SIRP1α TARGETED CHIMERIC PROTEINS AND USES THEREOF |
| EP3841112A1 (en) | 2018-08-24 | 2021-06-30 | Codiak BioSciences, Inc. | Extracellular vesicles targeting dendritic cells and uses thereof |
| JP7404343B2 (ja) * | 2018-09-04 | 2023-12-25 | ナンジン ユーマブ－バイオファーマ カンパニー リミテッド | 融合タンパク質、並びに腫瘍及び／又はウイルス感染の治療薬を製造するためのその使用 |
| US12162947B2 (en) * | 2018-09-04 | 2024-12-10 | Nanjing Umab-Biopharma Co., Ltd. | Fusion protein and its applicaton in preparing medicine for treating tumor and/or viral infection |
| CN120623346A (zh) * | 2018-10-11 | 2025-09-12 | 因荷布瑞克斯生物科学公司 | Pd-1单结构域抗体及其治疗组合物 |
| US12410225B2 (en) | 2018-11-08 | 2025-09-09 | Orionis Biosciences, Inc | Modulation of dendritic cell lineages |
| WO2020127369A1 (en) * | 2018-12-21 | 2020-06-25 | Ose Immunotherapeutics | Bifunctional molecule directed against human pd-1 |
| KR20210108978A (ko) * | 2018-12-21 | 2021-09-03 | 오제 이뮈노테라프틱스 | 이작용성 항-pd-1/il-7 분자 |
| PH12021551475A1 (en) * | 2019-01-07 | 2022-05-02 | Shattuck Labs Inc | Heterodimeric proteins for modulating gamma delta t cells |
| CN113795511B (zh) | 2019-01-23 | 2024-07-23 | 大有华夏生物医药集团有限公司 | 抗pd-l1双抗体及其用途 |
| CN111499718B (zh) * | 2019-01-30 | 2022-06-14 | 复旦大学 | 人α干扰素受体结合相关位点突变体及其用途 |
| CA3133141A1 (en) * | 2019-03-15 | 2020-09-24 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Combined pharmaceutical composition for treating small cell lung cancer |
| US11440943B2 (en) | 2019-03-28 | 2022-09-13 | Orionis Biosciences, Inc. | Therapeutic interferon alpha 1 proteins |
| US20220177550A1 (en) * | 2019-03-28 | 2022-06-09 | Orionis Biosciences, Inc. | Chimeric proteins and chimeric protein complexes directed to fms-like tyrosine kinase 3 (flt3) |
| US12351614B2 (en) * | 2019-03-28 | 2025-07-08 | Orionis Biosciences, Inc. | CLEC9A-based chimeric protein complexes |
| JP7773372B2 (ja) | 2019-03-28 | 2025-11-19 | オリオニス バイオサイエンシズ，インコーポレイテッド | 線維芽細胞活性化タンパク質結合物質およびその使用 |
| US11162079B2 (en) | 2019-05-10 | 2021-11-02 | The Regents Of The University Of California | Blood type O Rh-hypo-immunogenic pluripotent cells |
| BR112021023345A2 (pt) | 2019-05-20 | 2022-02-01 | Pandion Operations Inc | Imunotolerância com alvo em madcam |
| WO2020243134A1 (en) | 2019-05-27 | 2020-12-03 | Immatics US, Inc. | Viral vectors and their use in adoptive cellular therapy |
| EP3980051A4 (en) * | 2019-06-05 | 2023-09-13 | Asher Biotherapeutics, Inc. | FUSIONS OF MUTANT INTERLEUKIN-2 POLYPEPTIDES WITH ANTIGEN-BINDING MOLECULES TO MODULATE THE FUNCTION OF IMMUNE CELLS |
| CN114599390A (zh) * | 2019-06-10 | 2022-06-07 | 浙江冠科美博生物科技有限公司 | 抗体-白介素融合蛋白以及使用方法 |
| WO2020257412A1 (en) * | 2019-06-19 | 2020-12-24 | Orionis Biosciences, Inc. | Combination therapy with cd13-targeted chimeric proteins or chimeric protein complexes |
| EP4023679A4 (en) * | 2019-08-30 | 2023-10-04 | Nanjing Shunxin Pharmaceuticals Co., Ltd. of Chiatai Tianqing Pharmaceutical Group | FUSION PROTEIN TARGETING PD-L1 AND TGF-BETA AND USE THEREOF |
| TWI873176B (zh) * | 2019-09-04 | 2025-02-21 | 美商建南德克公司 | Ｃｄ８結合劑及其用途 |
| US20220378925A1 (en) * | 2019-09-26 | 2022-12-01 | Orionis Biosciences, Inc. | Conjugated chimeric proteins |
| WO2021062184A1 (en) * | 2019-09-26 | 2021-04-01 | Orionis Biosciences, Inc. | Pd-l1 targeted chimeric proteins and uses thereof |
| KR102402276B1 (ko) * | 2019-11-15 | 2022-05-26 | 주식회사 제넥신 | 변형된 인터루킨-7 및 tgf 베타 수용체 ii를 포함하는 융합단백질 및 이의 용도 |
| US20230242655A1 (en) | 2019-12-03 | 2023-08-03 | Evotec International Gmbh | Interferon-associated antigen binding proteins and uses thereof |
| CN113005088B (zh) * | 2019-12-19 | 2024-06-04 | 苏州方德门达新药开发有限公司 | 工程改造的t细胞、其制备及应用 |
| EP4107187A4 (en) | 2020-02-21 | 2024-07-03 | Pandion Operations, Inc. | TISSUE-TARGETED IMMUNOTOLERANCE WITH A CD39 EFFECTOR |
| DE102020111571A1 (de) * | 2020-03-11 | 2021-09-16 | Immatics US, Inc. | Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren |
| EP4157883A4 (en) * | 2020-06-02 | 2024-12-04 | Children's Medical Center Corporation | NANOBODY CONJUGATES (VHH) AND THEIR USES |
| JP7799638B2 (ja) * | 2020-06-30 | 2026-01-21 | チア タイ ティエンチン ファーマシューティカル グループ カンパニー リミテッド | 腫瘍を治療するための薬物 |
| WO2022011005A1 (en) * | 2020-07-07 | 2022-01-13 | Orionis Biosciences, Inc. | Immunostimulatory adjuvants |
| JP2023541601A (ja) | 2020-09-10 | 2023-10-03 | プレシリックス・ナームローゼ・ベンノートシヤープ | Ｆａｐに対する抗体フラグメント |
| TW202231292A (zh) | 2020-10-13 | 2022-08-16 | 美商健生生物科技公司 | 用於調節分化簇ｉｖ及／或ｖｉｉｉ的經生物工程改造之ｔ細胞介導之免疫力、材料、及其他方法 |
| JP2023550148A (ja) | 2020-11-20 | 2023-11-30 | シンシア・イノベーション・インコーポレイテッド | がん免疫治療に用いられる武装二重ｃａｒ－ｔ組成物及び方法 |
| WO2022111618A1 (zh) * | 2020-11-26 | 2022-06-02 | 正大天晴药业集团股份有限公司 | 用于治疗肺癌的抗PD-L1抗体和c-Met激酶抑制剂的联用药物组合物 |
| WO2022111562A1 (zh) * | 2020-11-26 | 2022-06-02 | 上海医药集团生物治疗技术有限公司 | 一种经修饰的免疫细胞及其应用 |
| JP2023553692A (ja) * | 2020-12-18 | 2023-12-25 | エフ． ホフマン－ラ ロシュ アーゲー | 標的治療のための前駆体タンパク質及びキット |
| CN112724199B (zh) * | 2020-12-30 | 2023-01-24 | 郑州大学 | 亲和Clec9a的多肽及其应用 |
| MX2023008081A (es) | 2021-01-11 | 2023-09-12 | Sana Biotechnology Inc | Uso de vectores virales dirigidos a cd8. |
| EP4288455A1 (en) | 2021-02-03 | 2023-12-13 | Mozart Therapeutics, Inc. | Binding agents and methods of using the same |
| IL286430A (en) | 2021-09-14 | 2023-04-01 | Yeda Res & Dev | Multispecific antibodies for use in the treatment of diseases |
| WO2023076876A1 (en) | 2021-10-26 | 2023-05-04 | Mozart Therapeutics, Inc. | Modulation of immune responses to viral vectors |
| WO2023114949A1 (en) | 2021-12-16 | 2023-06-22 | Sana Biotechnology, Inc. | Methods and systems of particle production |
| CN116375868A (zh) * | 2021-12-31 | 2023-07-04 | 康源博创生物科技(北京)有限公司 | 一种抗cd3的人源化抗体及其在制备双特异性抗体中的应用 |
| EP4463135A2 (en) | 2022-01-10 | 2024-11-20 | Sana Biotechnology, Inc. | Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses |
| CN115583995B (zh) * | 2022-01-30 | 2024-12-13 | 立凌生物制药(苏州)有限公司 | 双特异性抗体及其制备方法和应用 |
| WO2023150647A1 (en) | 2022-02-02 | 2023-08-10 | Sana Biotechnology, Inc. | Methods of repeat dosing and administration of lipid particles or viral vectors and related systems and uses |
| WO2023154785A2 (en) * | 2022-02-10 | 2023-08-17 | Orionis Biosciences, Inc. | Il-2 trap molecules |
| WO2023193015A1 (en) | 2022-04-01 | 2023-10-05 | Sana Biotechnology, Inc. | Cytokine receptor agonist and viral vector combination therapies |
| WO2023203135A1 (en) | 2022-04-22 | 2023-10-26 | Precirix N.V. | Improved radiolabelled antibody |
| AU2023264245A1 (en) | 2022-05-02 | 2024-12-19 | Precirix N.V. | Pre-targeting |
| WO2024026377A1 (en) | 2022-07-27 | 2024-02-01 | Sana Biotechnology, Inc. | Methods of transduction using a viral vector and inhibitors of antiviral restriction factors |
| WO2024040194A1 (en) | 2022-08-17 | 2024-02-22 | Capstan Therapeutics, Inc. | Conditioning for in vivo immune cell engineering |
| US20260055146A1 (en) | 2022-08-24 | 2026-02-26 | Sana Biotechnology, Inc. | Delivery of heterologous proteins |
| WO2024064838A1 (en) | 2022-09-21 | 2024-03-28 | Sana Biotechnology, Inc. | Lipid particles comprising variant paramyxovirus attachment glycoproteins and uses thereof |
| JP2024047762A (ja) | 2022-09-27 | 2024-04-08 | セイコーエプソン株式会社 | 成形用材料 |
| WO2024119157A1 (en) | 2022-12-02 | 2024-06-06 | Sana Biotechnology, Inc. | Lipid particles with cofusogens and methods of producing and using the same |
| WO2024145108A1 (en) * | 2022-12-28 | 2024-07-04 | Binacea Pharma, Inc. | Anti-cd8 antibodies and methods of use thereof |
| WO2024156881A1 (en) | 2023-01-27 | 2024-08-02 | Vib Vzw | CD8b-BINDING POLYPEPTIDES |
| WO2024220597A2 (en) | 2023-04-18 | 2024-10-24 | Sana Biotechnology, Inc. | Digital droplet based assay for detecting replication competent lentiviral vector |
| EP4709752A1 (en) * | 2023-05-08 | 2026-03-18 | F. Hoffmann-La Roche AG | Targeted interferon alpha fusion proteins and methods of use |
| EP4716750A1 (en) | 2023-05-23 | 2026-04-01 | Sana Biotechnology, Inc. | Tandem fusogens and related lipid particles |
| AU2024279278A1 (en) | 2023-05-31 | 2025-12-18 | Capstan Therapeutics, Inc. | Lipid nanoparticle formulations and compositions |
| CN116875550B (zh) * | 2023-09-08 | 2023-12-26 | 天津市肿瘤医院（天津医科大学肿瘤医院） | 一种FABP4+C1q+巨噬细胞及其制备方法和用途 |
| US20250127728A1 (en) | 2023-10-05 | 2025-04-24 | Capstan Therapeutics, Inc. | Constrained Ionizable Cationic Lipids and Lipid Nanoparticles |
| WO2025076113A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Ionizable cationic lipids with conserved spacing and lipid nanoparticles |
| US20250302763A1 (en) | 2024-02-22 | 2025-10-02 | Capstan Therapeutics, Inc. | Immune engineering amplification |
| WO2025184529A1 (en) | 2024-03-01 | 2025-09-04 | Sana Biotechnology, Inc. | Viral particles with fusogen display and related compositions and methods |
| WO2025217454A2 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Ionizable cationic lipids and lipid nanoparticles |
| WO2025217452A1 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
| WO2025260013A1 (en) | 2024-06-13 | 2025-12-18 | Yale University | Compositions and methods of mrna-based adjuvants for mrna vaccines |
| CN121378484A (zh) * | 2024-10-14 | 2026-01-23 | 北京大学 | 抗原结合蛋白及其应用 |
| CN120248112B (zh) * | 2025-06-04 | 2025-08-05 | 天津龙晟生物科技有限公司 | 一种叶酸单克隆抗体及其应用以及一种叶酸检测试剂盒 |
| CN120699170B (zh) * | 2025-08-22 | 2025-11-25 | 中生康元生物科技(北京)有限公司 | 一种三特异性单链抗体及其用途 |
Family Cites Families (155)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3536809A (en) | 1969-02-17 | 1970-10-27 | Alza Corp | Medication method |
| US3598123A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
| US4008719A (en) | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
| US4361549A (en) | 1979-04-26 | 1982-11-30 | Ortho Pharmaceutical Corporation | Complement-fixing monoclonal antibody to human T cells, and methods of preparing same |
| US4537776A (en) | 1983-06-21 | 1985-08-27 | The Procter & Gamble Company | Penetrating topical pharmaceutical compositions containing N-(2-hydroxyethyl) pyrrolidone |
| IE58110B1 (en) | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
| DE3853740T2 (de) | 1987-06-10 | 1995-11-09 | Dana Farber Cancer Inst Inc | Bifunktionelle Antikörperkonstruktionen und Verfahren zur selektiven Tötung von Zellbeständen. |
| US5073543A (en) | 1988-07-21 | 1991-12-17 | G. D. Searle & Co. | Controlled release formulations of trophic factors in ganglioside-lipsome vehicle |
| IT1229203B (it) | 1989-03-22 | 1991-07-25 | Bioresearch Spa | Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative. |
| DE69007975T2 (de) | 1989-08-22 | 1994-07-21 | Immunex Corp | Fusionsprotein bestehend aus gm-csf und il-3. |
| WO1991006319A1 (en) | 1989-10-27 | 1991-05-16 | Arch Development Corporation | Methods and compositions for promoting immunopotentiation |
| US6406696B1 (en) | 1989-10-27 | 2002-06-18 | Tolerance Therapeutics, Inc. | Methods of stimulating the immune system with anti-CD3 antibodies |
| US5120548A (en) | 1989-11-07 | 1992-06-09 | Merck & Co., Inc. | Swelling modulated polymeric drug delivery device |
| US6750325B1 (en) | 1989-12-21 | 2004-06-15 | Celltech R&D Limited | CD3 specific recombinant antibody |
| ES2259800T3 (es) | 1990-06-11 | 2006-10-16 | Gilead Sciences, Inc. | Procedimientos de uso de ligandos de acido nucleico. |
| US6277969B1 (en) | 1991-03-18 | 2001-08-21 | New York University | Anti-TNF antibodies and peptides of human tumor necrosis factor |
| US5580578A (en) | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
| SE9201966D0 (sv) | 1992-06-25 | 1992-06-25 | Trion Forskning & Utveckling | Interleukin-1beta deletion mutant |
| DK1621554T4 (da) | 1992-08-21 | 2012-12-17 | Univ Bruxelles | Immunoglobuliner blottet for lette kæder |
| US5591767A (en) | 1993-01-25 | 1997-01-07 | Pharmetrix Corporation | Liquid reservoir transdermal patch for the administration of ketorolac |
| US6491916B1 (en) | 1994-06-01 | 2002-12-10 | Tolerance Therapeutics, Inc. | Methods and materials for modulation of the immunosuppresive activity and toxicity of monoclonal antibodies |
| US5914254A (en) | 1993-08-02 | 1999-06-22 | Celtrix Pharmaceuticals, Inc. | Expression of fusion polypeptides transported out of the cytoplasm without leader sequences |
| US5595756A (en) * | 1993-12-22 | 1997-01-21 | Inex Pharmaceuticals Corporation | Liposomal compositions for enhanced retention of bioactive agents |
| SE9400088D0 (sv) | 1994-01-14 | 1994-01-14 | Kabi Pharmacia Ab | Bacterial receptor structures |
| IT1270594B (it) | 1994-07-07 | 1997-05-07 | Recordati Chem Pharm | Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida |
| DE69532127T2 (de) | 1994-07-20 | 2004-08-26 | Genetics Institute, Inc., Cambridge | Interaktions-fullensysteme zum nachweis von protein-interaktionen |
| EP0739981A1 (en) | 1995-04-25 | 1996-10-30 | Vrije Universiteit Brussel | Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes |
| WO1997010338A1 (en) | 1995-09-12 | 1997-03-20 | Chiron Corporation | Improved interleukin-6 receptor antagonist |
| DK0770397T3 (da) | 1995-10-18 | 2004-08-09 | Akzo Nobel Nv | Newcastle disease viruskombinationsvaccine |
| US5716946A (en) | 1996-02-13 | 1998-02-10 | Wisconsin Alumni Research Foundation | Multiple sclerosis treatment |
| US5834597A (en) | 1996-05-20 | 1998-11-10 | Protein Design Labs, Inc. | Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same |
| US5986059A (en) | 1996-06-14 | 1999-11-16 | Bayer Corporation | T-cell selective interleukin-4 agonists |
| US6653104B2 (en) | 1996-10-17 | 2003-11-25 | Immunomedics, Inc. | Immunotoxins, comprising an internalizing antibody, directed against malignant and normal cells |
| DE19742706B4 (de) | 1997-09-26 | 2013-07-25 | Pieris Proteolab Ag | Lipocalinmuteine |
| AU3596599A (en) | 1998-01-26 | 1999-08-09 | Unilever Plc | Method for producing antibody fragments |
| AUPP221098A0 (en) | 1998-03-06 | 1998-04-02 | Diatech Pty Ltd | V-like domain binding molecules |
| AU2001288405B8 (en) | 1998-04-03 | 2007-06-14 | The Penn State Research Foundation | Amino acid substitution mutants of interleukin 13 |
| US6818418B1 (en) | 1998-12-10 | 2004-11-16 | Compound Therapeutics, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
| DK1144616T4 (da) | 1999-01-19 | 2009-03-30 | Unilever Nv | Fremgangsmåde til fremstilling af antistoffragmenter |
| ATE320486T1 (de) | 1999-05-05 | 2006-04-15 | Phylogica Ltd | Isolierung von biologischen modulatoren aus bibiotheken mit biologisch vielfältigen genfragmenten |
| US6794144B1 (en) | 1999-05-26 | 2004-09-21 | Licentia Ltd. | Methods and materials for generating SH3 domains with tailored binding properties |
| JP2001026545A (ja) | 1999-07-09 | 2001-01-30 | Takara Shuzo Co Ltd | 免疫応答活性化製剤 |
| JP5004390B2 (ja) | 1999-08-23 | 2012-08-22 | デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド | 新規ｂ７−４分子およびその用途 |
| US7101974B2 (en) | 2000-03-02 | 2006-09-05 | Xencor | TNF-αvariants |
| US6613756B2 (en) | 2000-05-05 | 2003-09-02 | Wisconsin Alumni Research Foundation | Use of tetracycline derivatives in treating multiple sclerosis |
| SE0001877D0 (sv) | 2000-05-22 | 2000-05-22 | Klaus Mosbach | Molecular imprinting |
| US20030190598A1 (en) | 2000-05-26 | 2003-10-09 | Jasmid Tanha | Single-domain antigen-binding antibody fragments derived from llama antibodies |
| GB0014356D0 (en) | 2000-06-12 | 2000-08-02 | Colover Jack | Treatment of multiple sclerosis |
| US20020025304A1 (en) | 2000-06-16 | 2002-02-28 | Croze Edward M. | Novel interferon for the treatment of multiple sclerosis |
| EP1332209B1 (en) | 2000-09-08 | 2009-11-11 | Universität Zürich | Collections of repeat proteins comprising repeat modules |
| DE10053224A1 (de) | 2000-10-26 | 2002-05-08 | Univ Goettingen Georg August | Verfahren zur Exposition von Peptiden und Polypeptiden auf der Zelloberfläche von Bakterien |
| US20040132094A1 (en) | 2000-12-13 | 2004-07-08 | Michael Etzerodt | Combinatorial libraries of proteins having the scaffold structure of c-type lectinlike domains |
| GB0110029D0 (en) | 2001-04-24 | 2001-06-13 | Grosveld Frank | Transgenic animal |
| AU2002323501C1 (en) | 2001-08-30 | 2010-04-29 | Biorexis Technology, Inc | Modified transferrin fusion proteins |
| JP4213586B2 (ja) | 2001-09-13 | 2009-01-21 | 株式会社抗体研究所 | ラクダ抗体ライブラリーの作製方法 |
| JP2005289809A (ja) | 2001-10-24 | 2005-10-20 | Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) | 突然変異重鎖抗体 |
| IL149820A0 (en) | 2002-05-23 | 2002-11-10 | Curetech Ltd | Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency |
| AU2003281200A1 (en) | 2002-07-03 | 2004-01-23 | Tasuku Honjo | Immunopotentiating compositions |
| AU2003282724B2 (en) | 2002-10-02 | 2010-03-04 | Catalyst Biosciences, Inc. | Methods of generating and screening for proteases with altered specificity |
| WO2004041863A2 (en) | 2002-11-08 | 2004-05-21 | Ablynx N.V. | Single domain antibodies directed against interferon- gamma and uses therefor |
| GB0228210D0 (en) | 2002-12-03 | 2003-01-08 | Babraham Inst | Single chain antibodies |
| US20040253237A1 (en) | 2002-12-05 | 2004-12-16 | Ian Walters | Methods of treatment of ulcerative colitis with anti-CD3 antibodies |
| CN101899114A (zh) | 2002-12-23 | 2010-12-01 | 惠氏公司 | 抗pd-1抗体及其用途 |
| MXPA05007151A (es) | 2002-12-31 | 2005-09-21 | Nektar Therapeutics Al Corp | Polimeros terminados en maleimida hidroliticamente estables. |
| DK1587907T3 (da) | 2003-01-07 | 2011-04-04 | Dyax Corp | Kunitz-domænebibliotek |
| DK1629011T3 (da) | 2003-05-31 | 2010-05-03 | Micromet Ag | Humane anti-humane-DC3-bindingsmolekyler |
| TW200526780A (en) | 2004-01-06 | 2005-08-16 | Hayashibara Biochem Lab | TNF antagonists and TNF inhibitors comprising the same as the active ingredient |
| US20110020273A1 (en) | 2005-04-06 | 2011-01-27 | Ibc Pharmaceuticals, Inc. | Bispecific Immunocytokine Dock-and-Lock (DNL) Complexes and Therapeutic Use Thereof |
| CN101115769A (zh) * | 2004-05-19 | 2008-01-30 | 马克西根公司 | 干扰素-α多肽和偶联物 |
| CA2569509C (en) | 2004-06-03 | 2014-08-12 | Novimmune S.A. | Anti-cd3 antibodies and methods of use thereof |
| US20060008844A1 (en) | 2004-06-17 | 2006-01-12 | Avidia Research Institute | c-Met kinase binding proteins |
| JPWO2006006342A1 (ja) | 2004-07-12 | 2008-04-24 | 三菱電機株式会社 | 光学式エンコーダ |
| DE102004049479A1 (de) | 2004-10-11 | 2006-04-13 | Scil Proteins Gmbh | Proteinkonjugate zur Verwendung in Therapie, Diagnose und Chromatographie |
| EP1812038A1 (en) | 2004-11-18 | 2007-08-01 | VIB vzw | Fibronectin iii domain as leptin receptor antagonists |
| CA2587597A1 (en) | 2004-11-19 | 2006-05-26 | Biogen Idec Ma Inc. | Treatment for multiple sclerosis |
| WO2006115800A2 (en) | 2005-04-15 | 2006-11-02 | The Regents Of The University Of California | Enhanced wound healing utilizing an anti-her2 antibody coupled to a tnf alpha |
| DK2439273T3 (da) | 2005-05-09 | 2019-06-03 | Ono Pharmaceutical Co | Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika |
| US8188223B2 (en) | 2005-05-18 | 2012-05-29 | Ablynx N.V. | Serum albumin binding proteins |
| CA2611861C (en) * | 2005-06-08 | 2017-11-28 | The Brigham And Women's Hospital, Inc. | Methods and compositions for the treatment of persistent infections |
| GB0513047D0 (en) | 2005-06-27 | 2005-08-03 | Thermo Finnigan Llc | Electronic ion trap |
| PT1907424E (pt) | 2005-07-01 | 2015-10-09 | Squibb & Sons Llc | Anticorpos monoclonais humanos para o ligando 1 de morte programada (pd-l1) |
| TW200732347A (en) | 2005-10-06 | 2007-09-01 | Trophogen Inc | VEGF analogs and methods of use |
| US7947265B2 (en) | 2006-08-02 | 2011-05-24 | Mcgill University | Fusion proteins and methods for modulation of immune response |
| EP1892248A1 (en) | 2006-08-21 | 2008-02-27 | Eidgenössische Technische Hochschule Zürich | Specific and high affinity binding proteins comprising modified SH3 domains of FYN kinase |
| AU2007331672A1 (en) | 2006-12-15 | 2008-06-19 | Ablynx N.V. | Amino acid sequences that modulate the interaction between cells of the immune system |
| US9023352B2 (en) | 2007-02-20 | 2015-05-05 | Tufts University | Methods, compositions and kits for treating a subject using a recombinant heteromultimeric neutralizing binding protein |
| WO2008124086A2 (en) | 2007-04-05 | 2008-10-16 | President And Fellows Of Harvard College | Chimeric activators: quantitatively designed protein therapeutics and uses thereof |
| PL2185589T3 (pl) | 2007-06-01 | 2016-09-30 | Środki wiążące receptor regionu stałego Fc immunoglobuliny | |
| BR122017025062B8 (pt) | 2007-06-18 | 2021-07-27 | Merck Sharp & Dohme | anticorpo monoclonal ou fragmento de anticorpo para o receptor de morte programada humano pd-1, polinucleotídeo e composição compreendendo o referido anticorpo ou fragmento |
| WO2009003145A1 (en) | 2007-06-26 | 2008-12-31 | University Of Miami | Antibody-endostatin fusion protein and its variants |
| GB0805159D0 (en) * | 2008-03-19 | 2008-04-23 | Sancho Madrid David | Immune modulation via C-type lectin |
| CN101868246A (zh) | 2007-09-21 | 2010-10-20 | 加利福尼亚大学董事会 | 被导靶的干扰素显示强的细胞凋亡和抗肿瘤活性 |
| ES2386495T3 (es) | 2007-11-29 | 2012-08-21 | Molecular Health Gmbh | siARN específico de EPH-B4 para reducir el crecimiento de células neoplásicas inducidas por EPO durante el tratamiento de anemia en pacientes con cáncer, receptor de eritropoyetina protector de tejido (NEPOR) y métodos de uso |
| US20100285039A1 (en) | 2008-01-03 | 2010-11-11 | The Johns Hopkins University | B7-H1 (CD274) Antagonists Induce Apoptosis of Tumor Cells |
| CN101970499B (zh) | 2008-02-11 | 2014-12-31 | 治疗科技公司 | 用于肿瘤治疗的单克隆抗体 |
| EP2262837A4 (en) | 2008-03-12 | 2011-04-06 | Merck Sharp & Dohme | PD-1 BINDING PROTEINS |
| AU2009288730B2 (en) | 2008-08-25 | 2013-06-20 | Amplimmune, Inc. | Compositions of PD-1 antagonists and methods of use |
| JP2012500855A (ja) | 2008-08-25 | 2012-01-12 | アンプリミューン、インコーポレーテッド | Ｐｄ−１アンタゴニストおよび感染性疾患を処置するための方法 |
| WO2010030671A1 (en) | 2008-09-09 | 2010-03-18 | University Of Medicine And Dentistry Of New Jersey | Type i interferon antagonists |
| US8334101B2 (en) | 2008-09-26 | 2012-12-18 | University Of Massachusetts | Intracellular DNA receptor |
| US8552154B2 (en) | 2008-09-26 | 2013-10-08 | Emory University | Anti-PD-L1 antibodies and uses therefor |
| WO2010066740A1 (en) | 2008-12-08 | 2010-06-17 | Complix Nv | Single-chain antiparallel coiled coil proteins |
| EP3255060A1 (en) | 2008-12-09 | 2017-12-13 | F. Hoffmann-La Roche AG | Anti-pd-l1 antibodies and their use to enhance t-cell function |
| JP5844159B2 (ja) | 2009-02-09 | 2016-01-13 | ユニヴェルシテ デクス−マルセイユＵｎｉｖｅｒｓｉｔｅ Ｄ’Ａｉｘ−Ｍａｒｓｅｉｌｌｅ | Ｐｄ−１抗体およびｐｄ−ｌ１抗体ならびにその使用 |
| CA2755983A1 (en) * | 2009-03-23 | 2010-09-30 | The Walter And Eliza Hall Institute Of Medical Research | Compounds and methods for modulating an immune response |
| JP5764127B2 (ja) | 2009-08-17 | 2015-08-12 | ロシュ グリクアート アーゲー | 標的化イムノコンジュゲート |
| CA2772572A1 (en) * | 2009-08-31 | 2011-03-03 | Ibc Pharmaceuticals, Inc. | Bispecific immunocytokine dock-and-lock (dnl) complexes and therapeutic use thereof |
| JP2013504539A (ja) | 2009-09-10 | 2013-02-07 | サイトス バイオテクノロジー アーゲー | 糖尿病治療におけるインターロイキン１βムテイン・コンジュゲートの使用 |
| WO2011066342A2 (en) | 2009-11-24 | 2011-06-03 | Amplimmune, Inc. | Simultaneous inhibition of pd-l1/pd-l2 |
| PL2504364T3 (pl) | 2009-11-24 | 2017-12-29 | Medimmune Limited | Ukierunkowane środki wiążące przeciwko B7-H1 |
| US20110262348A1 (en) | 2010-03-29 | 2011-10-27 | Vrije Universiteit Brussel | Selective targeting of intratumoral cells |
| US8907053B2 (en) | 2010-06-25 | 2014-12-09 | Aurigene Discovery Technologies Limited | Immunosuppression modulating compounds |
| RU2577299C2 (ru) | 2011-07-04 | 2016-03-10 | Олег Ильич Эпштейн | Способ лечения инфекционных заболеваний и комплексное лекарственное средство для лечения инфекционных заболеваний |
| SG192673A1 (en) | 2011-02-10 | 2013-09-30 | Roche Glycart Ag | Mutant interleukin-2 polypeptides |
| JP6072771B2 (ja) | 2011-04-20 | 2017-02-01 | メディミューン，エルエルシー | Ｂ７−ｈ１およびｐｄ−１に結合する抗体およびその他の分子 |
| US9534056B2 (en) | 2011-06-06 | 2017-01-03 | Immungene Inc | Engineered TAA antibody-TNFSF member ligand fusion molecules |
| SE535863C2 (sv) | 2011-07-18 | 2013-01-22 | Atlas Copco Ind Tech Ab | Hållare för motordrivet verktyg innefattande klämdelar med genomgående hål |
| WO2013053008A2 (en) | 2011-10-14 | 2013-04-18 | The Walter And Eliza Hall Institute Of Medical Research | Molecules which bind clec9a |
| EP3559049B1 (en) | 2011-10-28 | 2025-06-11 | Teva Pharmaceuticals Australia Pty Ltd | Polypeptide constructs and uses thereof |
| ES2694180T3 (es) | 2012-01-20 | 2018-12-18 | Vib Vzw | Citocinas de haz alfa-helicoidal mutantes dirigidas |
| PT2822575T (pt) | 2012-03-03 | 2020-07-02 | Immungene Inc | Moléculas de fusão anticorpos-mutante de interferão modificadas |
| EP2872158A1 (en) | 2012-05-01 | 2015-05-20 | The University of Sydney | Vaccine and uses thereof |
| HK1203971A1 (en) | 2012-05-15 | 2015-11-06 | Bristol-Myers Squibb Company | Cancer immunotherapy by disrupting pd-1/pd-l1 signaling |
| EP2892924B1 (en) | 2012-06-14 | 2020-11-25 | Therapix Biosciences Ltd. | Humanized antibodies to cluster of differentiation 3 (cd3) |
| WO2013188693A1 (en) | 2012-06-15 | 2013-12-19 | Imaginab, Inc. | Antigen binding constructs to cd3 |
| US9783589B2 (en) * | 2012-08-13 | 2017-10-10 | Immungene Inc | Engineered antibody-interferon fusion molecules for treatment of autoimmune diseases |
| CN102775502A (zh) * | 2012-08-16 | 2012-11-14 | 天津禹王生物医药科技有限公司 | α干扰素融合蛋白 |
| KR20150131208A (ko) | 2013-03-13 | 2015-11-24 | 이미지냅 인코포레이티드 | Cd８에의 항원 결합 구조체들 |
| AU2014229282B2 (en) | 2013-03-15 | 2017-02-02 | Glaxosmithkline Intellectual Property (No.2) Limited | Low concentration antibody formulations |
| ME03675B (me) | 2013-07-05 | 2020-10-20 | Genmab As | Humanizovana ili himerna anтi-cd3 antiтela |
| KR102322510B1 (ko) | 2013-07-18 | 2021-11-08 | 브이아이비 브이지더블유 | 수용체 결합친화성이 현격히 감소된 사이토카인을 수반하는 푸소카인 |
| SG10202010429YA (en) | 2013-07-19 | 2020-11-27 | Vib Vzw | Targeting of cytokine antagonists |
| JP6595988B2 (ja) | 2013-07-19 | 2019-10-23 | ヴィブ ブイゼットダブリュー | ターゲットされる修飾ｔｎｆファミリーメンバー |
| BR112016001128A2 (pt) | 2013-07-19 | 2018-01-23 | Vib Vzw | membros da família il-1 modificados direcionados |
| PT3444271T (pt) * | 2013-08-08 | 2022-01-05 | Inst Nat Sante Rech Med | Modulocinas baseadas em il-15 e no domínio sushi de il-15ralfa |
| EA201690746A1 (ru) * | 2013-10-25 | 2016-12-30 | Фармасайкликс Элэлси | Лечение с применением ингибиторов тирозинкиназы брутона и иммунотерапии |
| CN103536917B (zh) * | 2013-10-30 | 2015-03-11 | 苏州丁孚靶点生物技术有限公司 | 干扰素在治疗肿瘤中的用途及相关的产品和方法 |
| PE20170255A1 (es) | 2014-01-24 | 2017-03-22 | Dana Farber Cancer Inst Inc | Moleculas de anticuerpo que se unen a pd-1 y usos de las mismas |
| UA119352C2 (uk) | 2014-05-01 | 2019-06-10 | Тева Фармасьютикалз Острейліа Пті Лтд | Комбінація леналідоміду або помалідоміду і конструкції анти-cd38 антитіло-атенуйований інтерферон альфа-2b та спосіб лікування суб'єкта, який має cd38-експресуючу пухлину |
| KR102762243B1 (ko) * | 2014-06-30 | 2025-02-05 | 알토 바이오사이언스 엘엘씨 | Il-15-베이즈드 분자 및 이의 사용 방법 |
| WO2016002263A1 (ja) | 2014-06-30 | 2016-01-07 | ソニー株式会社 | 無線通信装置、無線通信方法及びプログラム |
| EP3168717A4 (en) | 2014-07-11 | 2018-03-14 | Wacom Co., Ltd. | Position indicator, position detection device, and input control method for position detection device |
| CA2955612C (en) * | 2014-07-18 | 2022-05-17 | Advaxis, Inc. | Combination of a pd-1 antagonist and a listeria-based vaccine for treating prostate cancer |
| KR102476226B1 (ko) | 2014-08-05 | 2022-12-12 | 아폴로믹스 인코포레이티드 | 항-pd-l1 항체 |
| EP2982693A1 (en) | 2014-08-07 | 2016-02-10 | Affimed Therapeutics AG | CD3 binding domain |
| EP4245376A3 (en) | 2014-10-14 | 2023-12-13 | Novartis AG | Antibody molecules to pd-l1 and uses thereof |
| KR20230128139A (ko) | 2014-10-24 | 2023-09-01 | 아스트라제네카 아베 | 조합물 |
| US10544199B2 (en) * | 2014-10-29 | 2020-01-28 | Teva Pharmaceuticals Australia Pty Ltd | Interferon alpha 2B variants |
| CN104403004B (zh) * | 2014-11-24 | 2017-10-13 | 苏州丁孚靶点生物技术有限公司 | 抗体‑干扰素异二聚体的制备和用途 |
| WO2017077382A1 (en) | 2015-11-06 | 2017-05-11 | Orionis Biosciences Nv | Bi-functional chimeric proteins and uses thereof |
| US11661455B2 (en) * | 2016-02-05 | 2023-05-30 | Orionis Biosciences BV | Chimeric protein comprising an interferon alpha 2mutant and a PD-L1 binding moiety |
| CN116769054A (zh) * | 2016-02-05 | 2023-09-19 | 奥里尼斯生物科学私人有限公司 | 双特异性信号传导剂及其用途 |
| EP3455245A2 (en) * | 2016-05-13 | 2019-03-20 | Orionis Biosciences NV | Therapeutic targeting of non-cellular structures |
-
2017
- 2017-02-06 CN CN202310688728.7A patent/CN116769054A/zh active Pending
- 2017-02-06 CN CN201780021264.7A patent/CN109071663B/zh active Active
- 2017-02-06 DK DK17705564.7T patent/DK3411407T3/da active
- 2017-02-06 JP JP2018540141A patent/JP6991979B2/ja active Active
- 2017-02-06 EP EP17705564.7A patent/EP3411407B1/en active Active
- 2017-02-06 EP EP24168089.1A patent/EP4421094A3/en active Pending
- 2017-02-06 CA CA3013551A patent/CA3013551A1/en active Pending
- 2017-02-06 JP JP2018541133A patent/JP7236273B2/ja active Active
- 2017-02-06 EP EP22160584.3A patent/EP4059957A1/en active Pending
- 2017-02-06 US US16/075,312 patent/US10988538B2/en active Active
- 2017-02-06 CN CN201780021480.1A patent/CN109071632B/zh active Active
- 2017-02-06 CA CA3013555A patent/CA3013555A1/en active Pending
- 2017-02-06 EP EP17704697.6A patent/EP3411398B1/en active Active
- 2017-02-06 CN CN202310792348.8A patent/CN116813799A/zh active Pending
- 2017-02-06 WO PCT/EP2017/052550 patent/WO2017134305A1/en not_active Ceased
- 2017-02-06 US US16/075,317 patent/US11236166B2/en active Active
- 2017-02-06 DK DK17704697.6T patent/DK3411398T3/da active
- 2017-02-06 WO PCT/EP2017/052545 patent/WO2017134302A2/en not_active Ceased
- 2017-02-06 EP EP17703965.8A patent/EP3411065B1/en active Active
- 2017-02-06 EP EP17704207.4A patent/EP3411397A1/en not_active Withdrawn
- 2017-02-06 CN CN202310792382.5A patent/CN116854826A/zh active Pending
- 2017-02-06 CA CA3013554A patent/CA3013554A1/en active Pending
- 2017-02-06 CN CN201780021194.5A patent/CN108883180B/zh active Active
- 2017-02-06 CA CA3013558A patent/CA3013558C/en active Active
- 2017-02-06 ES ES17703965T patent/ES2877568T3/es active Active
- 2017-02-06 WO PCT/EP2017/052553 patent/WO2017134306A1/en not_active Ceased
- 2017-02-06 ES ES17705564T patent/ES2981745T3/es active Active
- 2017-02-06 CN CN202211603239.9A patent/CN115850521A/zh active Pending
- 2017-02-06 DK DK17703965.8T patent/DK3411065T3/da active
- 2017-02-06 CN CN201780021559.4A patent/CN109071627B/zh active Active
- 2017-02-06 EP EP21165264.9A patent/EP3909978A1/en active Pending
- 2017-02-06 CN CN202310688724.9A patent/CN117024599A/zh active Pending
- 2017-02-06 JP JP2018541357A patent/JP7030704B2/ja active Active
- 2017-02-06 JP JP2018541289A patent/JP7166923B2/ja active Active
- 2017-02-06 ES ES17704697T patent/ES2981730T3/es active Active
- 2017-02-06 EP EP21195070.4A patent/EP3998281A1/en active Pending
- 2017-02-06 WO PCT/EP2017/052544 patent/WO2017134301A1/en not_active Ceased
- 2017-02-06 US US16/075,318 patent/US11001631B2/en active Active
-
2020
- 2020-12-21 US US17/128,599 patent/US20210139586A1/en active Pending
-
2021
- 2021-04-05 US US17/222,043 patent/US12453770B2/en active Active
- 2021-12-17 US US17/554,180 patent/US12364753B2/en active Active
-
2022
- 2022-02-22 JP JP2022025686A patent/JP7386277B2/ja active Active
- 2022-07-08 JP JP2022110687A patent/JP2022153437A/ja active Pending
-
2024
- 2024-08-09 JP JP2024133824A patent/JP2024164840A/ja active Pending
-
2025
- 2025-06-16 US US19/238,731 patent/US20260069686A1/en active Pending